Contact Information

• Office: Room 333, Researching Building 18

• Email: mhhong@ecust.edu.cn

• Office Phone: +86 21 6425 2579

• Office Fax: +86 21 6425 3406

Education

• 2009.06  Ph.D.  Pharmaceutics, Fudan University, Shanghai, P. R. China

• 2004.06  B.S.  Pharmacy, Fudan University, Shanghai, P. R. China Professional Experience

• 2014.01-now  East China University of Science & Technology (Associate professor)

• 2010.08-2013.12  Shanghai Institute of Pharmaceutical Industry (Research scientist)

• 2009.07-2010.07  Shanghai PharmExplorer Co., Ltd (Research scientist, team leader)

Research Interests

Part I. Industrial Pharmacy-Preformulation and Formulation

Research direction I: crystal form screening of postmarket drug, which covers the studies on polymorphs, salts, solvates, hydrates and pharmaceutical cocrystals.

Research direction II: R&D in solid form dosage.

Research direction III: the polymorphism problem in pharmaceutical R&D process.

Part II. Targeted tumor therapy with nanoscale drug delivery systems

Targeting anticancer drugs to the tumor site with nanoscale delivery systems including liposomes, nanoparticles, niosomes and polymer-drug conjugates.

Publication

1. Hao Wu, Zhaizhu Deng, Bijian Zhou, Minghui Qi, Minghuang Hong^⁎, Guobin Ren^⁎. Improved transdermal permeability of ibuprofen by ionic liquid technology: Correlation between counterion structure and the physicochemical and biological properties, J. Mol. Liq., 2019, 283:399-409.

2. Minghuang Hong, Sai Guo, Kai Wang, Lei Ma^⁎, Guobin Ren^⁎, Influence factor investigation on the solution-mediated polymorphic transformation of Baricitinib phosphate, Z. Anorg. Allg. Chem., 2018, 644:849-855.

3. Minghuang Hong^#, Jingyan Chen^#, Hui Zhou, Hao Xu, Guobin Ren^⁎, Investigation of a solution-mediated phase transformation of pranlukast DMF solvate to hemihydrate, Cryst. Res. Technol., 2017, 52(6): 1700045.

4. Minghuang Hong^#, Shiwang Wu^#, Minghui Qi, Guobin Ren^⁎, Solubility correlation and thermodynamic analysis of two forms of metaxalone in different pure solvents, Fluid Phase Equilib., 2016, 409: 1-6.

5. Ming-Hui Qi^#, Ming-Huang Hong^#, Yan Liu, En-Fu Wang, Fu-Zheng Ren, Guo-Bin Ren^⁎, Estimating thermodynamic stability relationship of polymorphs of sofosbuvir, Cryst. Growth Des., 2015, 15(10): 5062-5067.

6. Minghuang Hong^#, Lehui Xu^#, Guobin Ren^⁎, Jinyao Chen, Minghui Qi, Solubility of lansoprazole in different solvents, Fluid Phase Equilib., 2012, 331: 18-25.

7. Minghuang Hong, Saijie Zhu, Yanyan Jiang, Guotao Tang, Chang Sun, Chao Fang, Bin Shi, and Yuanying Pei^⁎, Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles, J Control Release, 2010, 141: 22-29.

8. Minghuang Hong, Saijie Zhu, Yanyan Jiang, Guotao Tang, and Yuanying Pei^⁎, Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin, J Control Release,2009,133, 96-102.

9. Guo-Bin Ren^⁎, Ming-Huang Hong, Jia-Liang Zhong, Dong-Xu Yi, Le-Hui Xu, 2-{[3-Methyl-4-(2,2,2-trifluoroethoxy)-pyridin-2-yl]methylsulfanyl}-1H-benzimidazole monohydrate, Acta Cryst., 2011, E67: o270.

10. Saijie Zhu, Minghuang Hong, Guotao Tang, Lili Qian, Jiayuan Lin, Yanyan Jiang, and Yuanying Pei^⁎, Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style, Biomaterials, 2010, 31: 1360-1371.

11. Saijie Zhu, Minghuang Hong, Lihong Zhang, Guotao Tang, Yanyan Jiang, and Yuanying Pei^⁎, PEGylated PAMAM dendrimer-doxorubicin conjugates: in vitro evaluation, and in vivo tumor accumulation, Pharm. Res-Doror., 2010, 27: 161-173.

12. Saijie Zhu, Minghuang Hong, Chen Liu, and Yuanying Pei^⁎, Application of Box-Behnken design in understanding the quality of genistein self-nanoemulsified drug delivery systems and optimizing its formulation. Pharm. Dev. Technol., 2009, 14, 642-649.

13. Jinju Ma, Ming-Hui Qi, Ming-Huang Hong, Jie Lu, Guo-Bin Ren^⁎, 2-{[3-Methyl-4-(2,2,2-trifluoroethoxy)-pyridin-2-yl]methylsulfanyl}-1H-benzimidazole propan-2-ol monosolvate: a second monoclinic polymorph, Acta Cryst., 2012, E68: o2017

14. Yu-Feng Chen, Jin-Yao Chen, Ming-Huang Hong, Jie Lu, Guo-Bin Ren^⁎, 2-{[3-Methyl-4-(2,2,2-trifluoroethoxy)-pyridin-2-yl]methylsulfanyl}-1H-benzimidazole monohydrate: a monoclinic polymorph, Acta Cryst., 2012, E68: o2015-o2016

15. Wenhua Chen, Ne Guo, Minghui Qi, Haiying Dai, Minghuang Hong, Longfei Guan, Xiajuan Huan, Shanshan Song, Jinxue He, Yingqing Wang, Yong Xi, Xinying Yang, Yanyan Shen, Yi Su, Yiming Sun, Yinglei Gao, Yi Chen, Jian Ding, Yun Tang, Guobin Ren, Zehong Miao, Jian Li^⁎,Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy, Eur. J. Med. Chem., 2017, 138: 514-531

16. Saijie Zhu, Lili Qian, Minghuang Hong, Lihong Zhang, Yuanying Pei, and Yanyan Jiang^⁎, RGD-Modified PEG-PAMAM-DOX Conjugate: In vitro and in vivo targeting to both tumor neovascular endothelial cells and tumor cells. Adv. Mater., 2011, 23: 84-89.

17. Saijie Zhu, Rongqin Huang, Minghuang Hong, Yanyan Jiang, Zhuohan Hu, Chen Liu, Yuanying Pei^⁎, Effects of polyoxyethylene (40) stearate on the activity of P-glycoprotein and cytochrome P450. Eur. J Pharm. Sci., 2009, 37: 573-580.